Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib long-term rollover extension study
2023-506618-29-00Phase 2Authorised
- Sponsor
- GSK
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label, single-arm trial of niraparib in ovarian cancer, breast cancer and prostate cancer (PCa), sponsored by GSK. Primary endpoints: Safety and Adverse event coding. Planned start Sep 2021; status: authorised.
02
Drugs
niraparib
03
Conditions
ovarian cancerbreast cancerprostate cancer (PCa)
Beyond the preview
Go deeper on 2023-506618-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506618-29-00.